Tra2B — Transformer 2 Beta Homolog is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Transformer 2 Beta Homolog | |
|---|---|
| Gene Symbol | TRA2B |
| Full Name | Transformer 2 Beta Homolog |
| Chromosome | 3q27.2 |
| NCBI Gene ID | [64324](https://www.ncbi.nlm.nih.gov/gene/64324) |
| OMIM | 605200 |
| Ensembl ID | ENSG00000161940 |
| UniProt ID | [Q13595](https://www.uniprot.org/uniprot/Q13595) |
| Protein Class | RNA-binding protein, Splicing factor |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Alzheimer's Disease |
TRA2B (Transformer-2 beta homolog) is a crucial RNA-binding protein that regulates alternative splicing in neuronal cells. Originally discovered in Drosophila as a key regulator of sex determination, TRA2B has evolved to play essential roles in mammalian neural development and function. This protein recognizes and binds to specific exonic splicing enhancer (ESE) sequences, promoting the inclusion of alternatively spliced exons in mature mRNA transcripts. Dysregulation of TRA2B-mediated splicing has been implicated in multiple neurodegenerative diseases, making it an important therapeutic target.
TRA2B functions as a sequence-specific RNA-binding protein that promotes exon inclusion during pre-mRNA splicing. The protein contains an RNA recognition motif (RRM) that enables it to bind to conserved sequence motifs (typically "GAA" repeats) within exons. TRA2B typically functions as part of a heterodimeric complex with TRA2A, though TRA2B can also act independently.
Key functions include:
The TRA2B protein consists of:
TRA2B is ubiquitously expressed but shows particularly high expression in neuronal tissues. The protein localizes primarily to the nucleus where it performs its splicing regulatory functions. Alternative splicing produces multiple TRA2B isoforms with tissue-specific expression patterns.
TRA2B is strongly implicated in ALS pathogenesis through multiple mechanisms:
TRA2B dysfunction contributes to AD pathogenesis through:
Emerging evidence links TRA2B to PD:
TRA2B represents a promising therapeutic target:
Knockout studies in mice reveal:
| Aspect | Details |
|---|---|
| ALS | TRA2B mutations cause autosomal dominant ALS with onset typically in adulthood |
| Therapeutic Target | Modulating TRA2B activity may help restore proper splicing in neurodegeneration |
| Biomarker | TRA2B splicing patterns may serve as disease progression markers |
The study of Tra2B — Transformer 2 Beta Homolog has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.